GSK’s Blenrep in combo with BorDex receives China NMPA breakthrough therapy designation to treat relapsed/refractory multiple myeloma: London, UK Saturday, September 14, 2024, 0 ...

Japan’s MHLW accepts for review GSK’s NDA for Blenrep combinations in relapsed/refractory multiple myeloma: London, UK Wednesday, September 18, 2024, 10:00 Hrs [IST] GSK plc a ...

China’s NMPA granted BTD for Blenrep (belantamab mafodotin) combined with BorDex for the treatment of multiple myeloma.

Moderna pushed back its break-even goal by two years on Thursday as it delayed the timeline for developing several key ...

It also revealed that outside the US there are several class actions and in excess of 100 personal injury cases pending against GSK in Canada, along with a class action in Israel. The success of ...

The United Arab Emirates does not expect to resume talks with the U.S. about a multi-billion dollar deal for F-35 warplanes, ...

GIBF2 to invest US$ 6m in BioVersys ; BV100 Phase 1 study in China expected to start in 1H 2025 in preparation for a global ...

Dr. Kevin Tabb, CEO of Beth Israel Lahey Health ... She spent five years as a director at drugmaker GlaxoSmithKline, which at one point during her tenure had 14 research and licensing agreements ...

Expects to submit next-generation COVID vaccine for approval in 2024 Expects to submit flu/COVID combination vaccine for approval in 2024 Announces positive Phase 3 results for its RSV vaccine for ...

Calls for probe into ‘deeply disturbing’ killing of US-Turkish woman in occupied West Bank - UN and United States call for ...

The role of the pharmaceutical industry has become a matter of sharp public controversy after scandals like the role of Purdue Pharma in fueling the US opioid epidemic. From the HIV/AIDS crisis to the ...